Psychedelic-Assisted Therapy Update-Recording - Psychedelic-Assisted Therapy Update

Video Transcription

Video Summary

The talk reviewed the rapidly evolving field of psychedelic-assisted therapy for substance use disorders. It explained the history of psychedelics in medicine, their interruption by regulatory and political backlash, and their modern resurgence through recent clinical trials. The speaker focused on psilocybin, LSD, DMT/ayahuasca, MDMA, and ibogaine, describing their mechanisms, safety profiles, and therapeutic models, which combine limited drug dosing with preparation and integration psychotherapy.<br /><br />The strongest current evidence for substance use disorders is for psilocybin, especially for alcohol, tobacco, and possibly cocaine use disorders. Recent trials showed significant reductions in heavy drinking and smoking abstinence rates, with promising early results for cocaine cessation. DMT and ayahuasca show encouraging but still preliminary data. MDMA is best supported for PTSD, with potential relevance to addiction through trauma treatment and reduced alcohol use. Ibogaine has compelling anecdotal and observational signals for opioid use disorder but lacks controlled efficacy data and carries serious cardiac risks.<br /><br />Major challenges include weak blinding in psychedelic trials, small sample sizes, safety concerns, cost, workforce training, ethical boundary issues, and unequal access. The presentation concluded that psychedelics are promising but not yet ready for routine addiction medicine practice.

Keywords

psychedelic-assisted therapy

substance use disorders

psilocybin

alcohol use disorder

tobacco cessation

cocaine use disorder

MDMA

ibogaine

ayahuasca